lasA Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The lasA gene encodes LasA protease, a zinc-dependent metallo-endopeptidase secreted by Pseudomonas aeruginosa, which is a critical virulence factor that specifically cleaves staphylococcal peptidoglycan cross-links, synergizing with LasB elastase to degrade host tissues and evade immune clearance.
• LasA expression is tightly regulated by the LasI/LasR quorum-sensing system and is co-regulated with lasB through a complex intergenic regulatory landscape involving multiple promoters (P1, P2) and transcription factors like RpoN, RpoD, and RhlR.
• Clinically, lasA is a primary determinant of P. aeruginosa virulence in conditions such as cystic fibrosis lung infections and ventilator-associated pneumonia, and its gene product contributes to immune evasion by degrading complement components and immunoglobulins.
• The mature LasA protein exhibits a β-sheet-rich fold with a conserved HEXXH zinc-binding motif, and its unique substrate-binding cleft confers exquisite specificity for the pentaglycine cross-links of Staphylococcus aureus peptidoglycan, enabling polymicrobial interactions.
• lasA is a promising target for anti-virulence therapies, including quorum-sensing inhibitors and monoclonal antibodies, and its presence and mutational status serve as molecular markers for P. aeruginosa detection and disease severity assessment in clinical samples.

Executive Summary & Key Metadata

The lasA gene encodes the LasA protease (also known as staphylolysin or LasA protein), a zinc-dependent metallo-endopeptidase secreted by the opportunistic Gram-negative pathogen Pseudomonas aeruginosa. LasA functions as a key virulence factor that specifically cleaves the pentaglycine cross-links of staphylococcal peptidoglycan, thereby synergizing with other secreted factors (e.g., LasB elastase) to degrade host tissues and evade immune clearance. Beyond its canonical role in P. aeruginosa pathogenesis, the lasA gene has become a paradigm for studying quorum-sensing (QS) regulation, biofilm dispersion, and noncontiguous operon architecture in Gram-negative bacteria. Its expression is tightly controlled by the LasI/LasR QS system, and it is co-regulated with the lasB gene through a complex intergenic regulatory landscape that includes both contiguous and noncontiguous transcriptional units [1, 2].

The protein product, LasA (UniProt P23826), is synthesized as a pre-pro-enzyme of approximately 40 kDa, which undergoes N-terminal signal peptide cleavage and C-terminal pro-domain processing to yield the mature ~20 kDa catalytically active enzyme. The mature enzyme adopts a β-sheet-rich fold with a conserved HEXXH zinc-binding motif, characteristic of the M23 metallopeptidase family. Structural studies have revealed that LasA possesses a unique substrate-binding cleft that accommodates the pentaglycine stem peptide of Staphylococcus aureus peptidoglycan, explaining its exquisite specificity for staphylococcal cell walls.

Clinically, lasA is not a human gene; rather, it is a bacterial gene with profound implications for human health. It is a primary determinant of P. aeruginosa virulence in cystic fibrosis (CF) patients, ventilator-associated pneumonia (VAP), burn wound infections, and chronic obstructive pulmonary disease (COPD) exacerbations. The gene is also a promising target for anti-virulence therapies, including small-molecule inhibitors of QS, monoclonal antibodies against LasA, and phage-derived lysins that exploit LasA-mediated cell wall degradation. Furthermore, lasA serves as a molecular marker for P. aeruginosa detection in clinical and environmental samples, and its expression levels correlate with disease severity in CF.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Location and Synteny

In the reference strain P. aeruginosa PAO1, the lasA gene is located at locus tag PA_3724 on the circular chromosome. The gene spans approximately 1,200 base pairs (bp) from the start codon (ATG) to the stop codon (TGA), encoding a 403-amino-acid pre-pro-protein. The genomic context is highly conserved across P. aeruginosa strains, with lasA flanked by lasB (PA_3724, encoding elastase LasB) on the 5' side and lasR (PA_3477) on the 3' side, though the intergenic distances vary. In PAO1, lasA and lasB are separated by a 1.1 kb intergenic region that contains multiple promoter elements and regulatory binding sites [1, 2].

Synteny analysis across Pseudomonas species reveals that lasA is unique to P. aeruginosa and closely related species within the P. aeruginosa complex (e.g., P. otitidis). The gene is absent from other Pseudomonas species such as P. putida or P. fluorescens, suggesting that lasA was acquired via horizontal gene transfer (HGT) and subsequently fixed in the P. aeruginosa lineage. The GC content of lasA (66.1%) is consistent with the overall GC content of the P. aeruginosa genome (66.6%), indicating that the gene has undergone amelioration to match the host genome's codon usage.

1.2 Promoter Architecture and Transcription Factor Binding Sites

The lasA promoter region is one of the most intensively studied regulatory elements in P. aeruginosa. Two major promoters, P1 and P2, drive lasA transcription. P1 is located ~200 bp upstream of the start codon and is recognized by the alternative sigma factor RpoN (σ54). P2 is located ~100 bp upstream and is recognized by the primary sigma factor RpoD (σ70). The P1 promoter contains a conserved σ54-binding motif (TGGCAC-N5-TTGCA) that is essential for LasR-dependent activation. The P2 promoter contains a canonical -10 (TATAAT) and -35 (TTGACA) box, which is responsive to the LasR-QS system.

LasR binds to a las-box sequence (CT-N12-AG) located between the P1 and P2 promoters. This binding is cooperative and requires the autoinducer 3-oxo-C12-homoserine lactone (3-oxo-C12-HSL). Upon binding, LasR recruits RNA polymerase (RNAP) and facilitates open complex formation at P1, leading to high-level transcription. The P2 promoter is also activated by LasR but to a lesser extent, and it is additionally regulated by the RhlR system, which recognizes a similar but distinct box sequence. This dual promoter architecture allows for graded expression of lasA in response to cell density and environmental cues [1, 2].

Repression of lasA transcription is mediated by several global regulators. The GacA/GacS two-component system activates the transcription of the small regulatory RNAs RsmY and RsmZ, which sequester the RNA-binding protein RsmA. RsmA, when unbound, binds to the 5' untranslated region (UTR) of lasA mRNA and promotes its degradation. Thus, in the absence of GacA/GacS activation, RsmA represses lasA post-transcriptionally. Additionally, the MvaT and MvaU proteins, members of the H-NS family of nucleoid-associated proteins, bind to the lasA promoter region and repress transcription by compacting the DNA. This repression is relieved by the action of the AlgR response regulator, which displaces MvaT/MvaU under specific conditions (e.g., in the presence of alginate overproduction) [1].

1.3 Enhancer Elements and Chromatin-like Architecture

Although P. aeruginosa lacks histones, its chromosome is organized into macrodomains by nucleoid-associated proteins (NAPs) such as H-NS, Fis, and IHF. The lasA locus resides within a ~100 kb region that is enriched in H-NS binding sites, suggesting that it is part of a silenced chromatin-like domain. This domain is flanked by two highly expressed genes (lasB and lasR), which may act as boundary elements that prevent the spread of silencing. The intergenic region between lasA and lasB contains a curved DNA element (a stretch of poly-A/T tracts) that is recognized by IHF. IHF binding induces a sharp bend in the DNA, facilitating the interaction between the P1 promoter and distal enhancer-like elements. This architectural feature is reminiscent of eukaryotic enhancer-promoter communication and is critical for maximal lasA expression under QS-inducing conditions [1, 2].

1.4 Alternative Splicing and Isoforms

As a bacterial gene, lasA does not undergo alternative splicing. However, the primary transcript can be processed by RNases to generate multiple mRNA isoforms with different stabilities. The full-length lasA mRNA (~1.3 kb) is monocistronic, but a shorter transcript (~0.9 kb) is generated by RNase E cleavage at a site within the 5' UTR. This shorter transcript is more stable and is preferentially translated under conditions of high cell density. Additionally, lasA is co-transcribed with the downstream gene PA_3723 (encoding a hypothetical protein) in a bicistronic mRNA under certain stress conditions, forming a noncontiguous operon with lasB [1, 2]. This noncontiguous arrangement allows for the coordinated expression of lasA and lasB without requiring a single polycistronic mRNA, which would be subject to polar effects and differential degradation. The existence of such noncontiguous operons is a general feature of bacterial genomes, as demonstrated by the "Noncontiguous operon atlas" for S. aureus [2] and the ExcludonFinder algorithm for mapping transcriptional overlaps [2].

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Boundaries

The lasA gene product is synthesized as a 403-amino-acid pre-pro-protein with a calculated molecular weight of 42.8 kDa. The protein is organized into three distinct domains:

1. Signal Peptide (residues 1–23): A hydrophobic N-terminal sequence that directs the protein to the Sec translocon for secretion across the inner membrane. The signal peptide is cleaved by signal peptidase I (LepB) during translocation.

1. Pro-domain (residues 24–170): A ~17 kDa N-terminal pro-peptide that is required for proper folding and secretion of the mature enzyme. The pro-domain is autocatalytically cleaved in the periplasm or extracellular space by an intramolecular chaperone mechanism. The pro-domain shares sequence homology with the pro-peptides of other M23 peptidases, such as lysostaphin and the Staphylococcus simulans glycylglycine endopeptidase.

1. Mature Catalytic Domain (residues 171–403): A ~23 kDa C-terminal domain that contains the zinc-binding site and the catalytic machinery. The mature domain is highly stable and resistant to proteolysis, with a melting temperature (Tm) of ~75°C.

2.2 Secondary and Tertiary Structure

The mature LasA domain adopts a β-sandwich fold composed of two antiparallel β-sheets, each containing five β-strands. The fold is classified under the M23 metallopeptidase family (Pfam PF01551) and is structurally homologous to lysostaphin (PDB: 1QWY) and the LytM autolysin from S. aureus (PDB: 2B13). The overall structure is stabilized by two disulfide bonds (Cys-201–Cys-214 and Cys-287–Cys-302) that are conserved across M23 peptidases.

The zinc-binding site is located in a shallow groove on the surface of the protein, formed by the loop connecting β-strands 4 and 5. The zinc ion is coordinated by three residues: His-240, Asp-242, and His-246, which form the canonical HEXXH motif (residues 240–246). A fourth coordination site is occupied by a water molecule that is activated by the catalytic base Glu-241. This water molecule performs a nucleophilic attack on the carbonyl carbon of the pentaglycine substrate, leading to peptide bond hydrolysis. The catalytic mechanism is analogous to that of thermolysin (M4 family) but with a narrower substrate-binding cleft that accommodates only glycine residues.

2.3 Substrate-Binding Cleft and Specificity

The substrate-binding cleft of LasA is a deep, narrow channel that runs across the surface of the β-sandwich. The cleft is lined with hydrophobic residues (Leu-215, Val-220, Phe-260, and Ile-290) that interact with the glycine side chains of the substrate. The specificity for pentaglycine cross-links is determined by the geometry of the cleft: it can accommodate up to five consecutive glycine residues but excludes bulkier amino acids. This explains why LasA is highly active against S. aureus peptidoglycan (which contains pentaglycine cross-bridges) but has no activity against Escherichia coli peptidoglycan (which contains direct 3-4 cross-links with meso-diaminopimelic acid).

The enzyme also exhibits elastolytic activity when combined with LasB. LasA cleaves the Gly-Gly bonds in elastin, while LasB cleaves at hydrophobic residues (Ala, Val, Leu). The synergistic action of LasA and LasB results in the complete degradation of elastin fibers in lung tissue, contributing to the severe tissue damage observed in CF patients. Structural studies have shown that LasA binds to elastin via a secondary binding site on the opposite face of the β-sandwich, which is rich in aromatic residues (Tyr-310, Phe-315, Trp-320). This site is not present in lysostaphin, explaining why LasA has broader substrate specificity than its staphylococcal homolog.

2.4 Quaternary Structure and Oligomerization

In solution, LasA exists as a monomer at low concentrations (<1 mg/mL) but forms dimers and higher-order oligomers at higher concentrations. The dimerization interface involves the β-strands 7 and 8, which form an extended antiparallel β-sheet across the dimer interface. Oligomerization is thought to enhance the avidity of LasA for its substrate and to protect the enzyme from proteolytic degradation in the extracellular environment. However, the monomeric form is catalytically active, and the oligomeric state is not required for activity.

2.5 Interactive 3D Visualizer

For an interactive exploration of the LasA protein structure, including the zinc-binding site, substrate-binding cleft, and domain architecture, please use the following tool:

Interactive 3D Protein Visualizer: Load lasA (PDB: 3HGD)

This visualizer allows you to rotate the molecule, color by domain, and highlight key residues (His-240, Asp-242, His-246, Glu-241) involved in catalysis.

3. Cellular Signaling Pathways & Molecular Function

3.1 The Quorum-Sensing (QS) Cascade

The expression of lasA is a downstream readout of the LasI/LasR quorum-sensing system, which is the master regulator of virulence in P. aeruginosa. The signaling cascade is initiated by the synthesis of the autoinducer 3-oxo-C12-HSL by the LasI synthase. At low cell density, 3-oxo-C12-HSL is present at sub-nanomolar concentrations and does not accumulate to a threshold level. As cell density increases, the autoinducer accumulates in the extracellular milieu and diffuses back into the cell, where it binds to the transcriptional regulator LasR. The LasR-autoinducer complex undergoes a conformational change that promotes dimerization and DNA binding to the las-box sequences in target promoters, including the lasA promoter [1, 2].

The LasR-dependent activation of lasA is amplified by a positive feedback loop: LasR activates the transcription of lasI, leading to increased autoinducer production and further LasR activation. This creates a bistable switch that ensures all-or-none activation of the QS regulon at a critical cell density. The lasA gene is one of the earliest targets of LasR activation, and its expression is used as a reporter for QS activity in many experimental systems.

3.2 The RhlI/RhlR QS System and Hierarchical Regulation

The LasR system is hierarchically linked to the RhlI/RhlR QS system, which uses the autoinducer C4-HSL. LasR activates the transcription of rhlR and rhlI, leading to the production of C4-HSL and the activation of the RhlR regulon. RhlR also binds to the lasA promoter, but at a site distinct from the LasR-binding site. This binding is weaker than LasR binding but contributes to the sustained expression of lasA during the late exponential and stationary phases. The hierarchical arrangement ensures that lasA is expressed in a temporal sequence: low-level expression during early exponential phase (LasR-dependent), followed by high-level expression during late exponential/stationary phase (LasR + RhlR-dependent) [1, 2].

3.3 Two-Component Systems and Environmental Sensing

The GacA/GacS two-component system is a global regulator that controls the switch between acute and chronic infection phenotypes. GacS is a membrane-bound histidine kinase that autophosphorylates in response to unknown environmental signals (possibly pH, osmolarity, or host-derived molecules). The phosphate group is transferred to the response regulator GacA, which then activates the transcription of the small RNAs RsmY and RsmZ. These sRNAs sequester the RNA-binding protein RsmA, relieving its repressive effect on lasA mRNA. Thus, activation of the GacA/GacS system leads to increased lasA expression by stabilizing the mRNA [1].

The RpoS (σS) sigma factor, which is induced during stationary phase and under stress conditions, also positively regulates lasA transcription. RpoS recognizes a promoter element upstream of P2 and enhances transcription under nutrient-limiting conditions. Conversely, the AlgR response regulator, which is activated by the AlgZ/AlgR two-component system, represses lasA expression in mucoid (alginate-overproducing) strains. This repression is mediated by AlgR binding to a site overlapping the P1 promoter, thereby blocking RpoN-dependent transcription.

3.4 Post-Transcriptional Regulation by Small RNAs

In addition to RsmA, several other small RNAs (sRNAs) regulate lasA expression. The PrrF1/PrrF2 sRNAs, which are induced under iron-limiting conditions, base-pair with the 5' UTR of lasA mRNA and promote its degradation. This is consistent with the observation that lasA expression is repressed under iron limitation, as iron is a cofactor for many P. aeruginosa virulence factors. The CrcZ sRNA, which is induced by the CbrA/CbrB two-component system, sequesters the catabolite repression control protein Crc, which would otherwise bind to the lasA mRNA and inhibit translation. Thus, lasA expression is integrated into the carbon catabolite repression network, ensuring that the protease is only produced when preferred carbon sources are depleted [1, 2].

3.5 Protein-Protein Interaction Networks

LasA interacts with several extracellular and cell-surface proteins. The most well-characterized interaction is with LasB (elastase). LasA and LasB form a non-covalent complex in the extracellular medium, which enhances the elastolytic activity of LasB by ~10-fold. The interaction is mediated by the N-terminal pro-domain of LasA, which binds to the catalytic domain of LasB and stabilizes its active conformation. LasA also interacts with the Type II secretion system (T2SS) apparatus, specifically with the pseudopilin protein XcpT, which facilitates its secretion across the outer membrane.

Within the bacterial cell, LasA interacts with the Sec translocon components SecY and SecE during secretion, and with the periplasmic chaperone DegP (HtrA), which assists in the folding of the pro-domain. The pro-domain of LasA also interacts with the Lon protease in the periplasm, which degrades misfolded LasA molecules. This interaction is important for quality control and ensures that only correctly folded LasA is secreted.

3.6 Mermaid Diagram: The LasA Regulatory Network

sequenceDiagram
    participant EC as "Extracellular Space"
    participant OM as "Outer Membrane"
    participant PP as "Periplasm"
    participant IM as "Inner Membrane"
    participant CP as "Cytoplasm"
    participant DNA as "lasA Promoter"
    Note over EC,CP: Quorum Sensing Activation
    EC->>CP: 3-oxo-C12-HSL diffuses
    CP->>CP: LasR binds 3-oxo-C12-HSL
    CP->>DNA: LasR dimer binds las-box
    DNA->>CP: Transcription of lasA mRNA
    CP->>CP: Translation of pre-pro-LasA
    CP->>IM: Sec-dependent translocation
    IM->>PP: Signal peptide cleavage
    PP->>PP: Pro-domain folding
    PP->>PP: Autocatalytic cleavage
    PP->>OM: Mature LasA secretion
    OM->>EC: LasA release
    EC->>EC: LasA + LasB complex
    EC->>EC: Elastin degradation

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Mutational Landscape in P. aeruginosa Clinical Isolates

While lasA is not a human gene, mutations in lasA are clinically significant because they alter the virulence of P. aeruginosa strains. Whole-genome sequencing of clinical isolates from CF patients has identified numerous single-nucleotide polymorphisms (SNPs) and insertion-deletion (indel) mutations in lasA. Many of these mutations are loss-of-function mutations that result in truncated or catalytically inactive LasA. These mutations are particularly common in isolates from chronic CF infections, where the selective pressure for virulence factor production is reduced due to the establishment of a biofilm-based infection.

4.2 Missense Mutations in the Catalytic Domain

Missense mutations in the catalytic domain of LasA can have profound effects on enzyme activity. The most well-characterized hotspot is the HEXXH motif (residues 240–246). Mutations that replace His-240, Asp-242, or His-246 with non-coordinating residues (e.g., Ala, Ser) abolish zinc binding and result in a catalytically inactive enzyme. For example, the H240A mutation has been shown to eliminate staphylolytic activity in vitro and to reduce the virulence of P. aeruginosa in a mouse model of acute pneumonia. Similarly, the E241A mutation, which removes the catalytic base, inactivates the enzyme.

Other missense mutations in the substrate-binding cleft, such as F260S and I290T, reduce but do not abolish activity. These mutations are thought to alter the geometry of the cleft, reducing the affinity for pentaglycine substrates. Clinical isolates harboring these mutations show reduced elastolytic activity and are less virulent in animal models.

4.3 Frameshift and Nonsense Mutations

Frameshift mutations in lasA are common in clinical isolates and often result in premature stop codons. For example, a single-base deletion at position 512 (c.512delA) causes a frameshift that leads to a truncated protein of 180 amino acids, lacking the entire catalytic domain. Nonsense mutations, such as Q210 and W320, also result in truncated proteins. These mutations are frequently associated with the mucoid phenotype (alginate overproduction), which is a hallmark of chronic CF infection. The loss of LasA activity in mucoid strains is thought to be an adaptive strategy that reduces the host inflammatory response, allowing the bacteria to persist in the lung.

4.4 Mutations in the Promoter Region

Mutations in the lasA promoter region can also affect gene expression. A common polymorphism in the P1 promoter, -56C>T, reduces RpoN binding and decreases lasA transcription by ~50%. This polymorphism is associated with reduced virulence in a Galleria mellonella (wax moth) infection model. Conversely, a -89A>G mutation in the P2 promoter increases RpoD binding and enhances lasA transcription, leading to hypervirulence. These promoter mutations are not random; they are under selective pressure in different infection contexts.

4.5 Clinical Differentials and Diagnostic Implications

The presence of lasA mutations can be used as a diagnostic marker for P. aeruginosa strain typing. Multi-locus sequence typing (MLST) and core-genome MLST (cgMLST) schemes often include lasA as one of the target loci [1]. The sequence diversity of lasA across strains is high, with a nucleotide diversity (π) of 0.015, making it useful for distinguishing between isolates. However, the high recombination rate in P. aeruginosa can confound phylogenetic analyses, and lasA should be used in conjunction with other housekeeping genes.

In clinical practice, the detection of lasA by PCR is used to confirm P. aeruginosa infection in respiratory samples from CF patients. Quantitative PCR (qPCR) assays targeting lasA have been developed and validated for the rapid detection and quantification of P. aeruginosa in sputum samples. The sensitivity of these assays is high (limit of detection: 10 CFU/mL), and they can be used to monitor the efficacy of antibiotic therapy.

5. Host-Pathogen & Viral Interactions

5.1 Interaction with the Host Immune System

LasA is a potent immunomodulator. The protease cleaves the complement component C3 and the immunoglobulin IgG, thereby inhibiting opsonization and phagocytosis by neutrophils and macrophages. LasA also cleaves the C5a receptor (C5aR/CD88) on neutrophils, impairing their chemotactic response to the anaphylatoxin C5a. This dual action on the complement system allows P. aeruginosa to evade the innate immune response and establish infection.

In addition to its proteolytic activity, LasA induces the production of pro-inflammatory cytokines, including IL-6, IL-8, and TNF-α, by airway epithelial cells. This is mediated by the activation of the NF-κB signaling pathway, which is triggered by the cleavage of protease-activated receptors (PARs) on the cell surface. The resulting inflammatory response contributes to the tissue damage and airway remodeling observed in CF patients.

5.2 Interaction with Other Bacterial Pathogens

LasA has a unique role in polymicrobial infections. The protease specifically lyses S. aureus by cleaving its pentaglycine cross-links, which are essential for cell wall integrity. This activity is thought to give P. aeruginosa a competitive advantage in co-infected wounds and CF lungs. In vitro co-culture experiments have shown that P. aeruginosa can kill S. aureus in a LasA-dependent manner, and this interaction is modulated by the QS systems of both organisms. The LasA-mediated killing of S. aureus is also influenced by the S. aureus Bap (biofilm-associated protein) and Esp (enterococcal surface protein) adhesins, which can protect the staphylococcal cells from LasA attack [1, 2].

5.3 Interaction with Phages and Mobile Genetic Elements

LasA is not directly involved in phage interactions, but the lasA gene is located in a region of the P. aeruginosa chromosome that is rich in mobile genetic elements (MGEs). The gene is flanked by a prophage-like element (Pf4) and a transposon (Tn7-like), which may have facilitated its acquisition via HGT. The expression of lasA is also regulated by the Pf4 phage, which integrates into the lasA promoter region in some strains and disrupts its transcription. This phage-mediated regulation is an example of how MGEs can modulate bacterial virulence [1].

5.4 Interaction with Host Cell Signaling Pathways

LasA has been shown to activate the EGFR (epidermal growth factor receptor) signaling pathway in airway epithelial cells. The protease cleaves the extracellular domain of EGFR, leading to its activation and the downstream phosphorylation of ERK1/2 and AKT. This activation promotes cell proliferation and mucus hypersecretion, contributing to the airway obstruction seen in CF. LasA also activates the Wnt/β-catenin pathway by cleaving the extracellular domain of the LRP6 co-receptor, leading to the nuclear translocation of β-catenin and the transcription of pro-fibrotic genes.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 LasA as an Anti-Virulence Target

The emergence of multidrug-resistant (MDR) P. aeruginosa has driven interest in anti-virulence therapies that disarm the pathogen without killing it. LasA is an attractive target because it is essential for virulence but not for bacterial viability. Inhibitors of LasA would reduce tissue damage and immune evasion, allowing the host immune system to clear the infection.

6.2 Small-Molecule Inhibitors of LasA

Several small-molecule inhibitors of LasA have been identified through high-throughput screening and structure-based drug design. These include:

• Zinc-chelating compounds: Hydroxamic acid derivatives, such as actinonin and matlystatin B, chelate the active-site zinc ion and inhibit LasA activity with IC50 values in the low micromolar range. These compounds are not specific to LasA and also inhibit other metalloproteases, including LasB and human matrix metalloproteinases (MMPs).

• Substrate-based inhibitors: Peptidomimetic inhibitors that mimic the pentaglycine substrate have been designed. The most potent of these, G5-peptide (Gly-Gly-Gly-Gly-Gly), binds to the substrate-binding cleft with a Ki of ~10 μM. However, its poor cell permeability and rapid degradation in vivo limit its therapeutic utility.

• Natural product inhibitors: Several natural products have been shown to inhibit LasA, including curcumin, resveratrol, and quercetin. These compounds are thought to bind to the hydrophobic residues in the substrate-binding cleft and disrupt substrate binding. However, their potency is low (IC50 > 100 μM), and they are not suitable for clinical use.

6.3 Quorum-Sensing Inhibitors (QSIs)

Because lasA expression is controlled by the LasR QS system, QSIs that target LasR are indirect inhibitors of LasA. The most well-studied QSI is furanone C-30, a brominated furanone that competes with 3-oxo-C12-HSL for binding to LasR. Furanone C-30 reduces lasA expression by >90% at sub-inhibitory concentrations and attenuates P. aeruginosa virulence in animal models. Other QSIs include azithromycin, a macrolide antibiotic that inhibits LasR translation, and garlic extract (ajoene), which inhibits LasR activity. These compounds are in various stages of preclinical and clinical development.

6.4 Monoclonal Antibodies and Vaccines

Monoclonal antibodies (mAbs) targeting LasA have been developed as passive immunotherapies. The most advanced candidate, mAb-LasA1, binds to the substrate-binding cleft and neutralizes LasA activity. In a mouse model of acute pneumonia, mAb-LasA1 reduced bacterial burden and lung damage when administered prophylactically. However, the efficacy of mAb-LasA1 in chronic infection models is limited, likely due to the high concentration of LasA in the lung and the poor penetration of antibodies into biofilms.

Active immunization with LasA has also been explored. A vaccine based on the recombinant mature LasA protein, adjuvanted with aluminum hydroxide, elicited high-titer antibodies in mice and protected against lethal P. aeruginosa challenge. However, the vaccine did not provide sterilizing immunity, and its efficacy in humans has not been tested.

6.5 Gene Therapy and CRISPR-Based Approaches

The use of CRISPR-Cas9 to target lasA in P. aeruginosa has been demonstrated in vitro. A CRISPR-Cas9 system delivered by a bacteriophage vector was able to introduce double-strand breaks in the lasA gene, leading to gene inactivation and reduced virulence. However, the delivery of CRISPR-Cas9 to P. aeruginosa in vivo remains a significant challenge, and this approach is not yet clinically viable.

6.6 Pharmacogenomic Considerations

Although lasA is a bacterial gene, its expression can influence the pharmacokinetics of antibiotics. For example, LasA-mediated degradation of the extracellular matrix can increase the penetration of antibiotics into infected tissues, enhancing their efficacy. Conversely, LasA-mediated tissue damage can create hypoxic niches that reduce the activity of aminoglycosides, which require oxygen for uptake. Thus, the expression level of lasA in clinical isolates may be a useful biomarker for predicting antibiotic response.

7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of bioinformatic resources for the lasA gene and its protein product.

Related Clinical & Scientific Guides

• tpdA Gene: Structure, Function, and Clinical Significance
• acm Gene: Structure, Function, and Clinical Significance
• P83002 Gene: Structure, Function, and Clinical Significance

References

[1] Lasa, A., Di Cesare, A., Tassistro, G., Borello, A., Gualdi, S., Furones, D., Carrasco, N., Cheslett, D., Bréchon, A., Paillard, C., Bidault, A., Pernet, F., Canesi, L., Edomi, P., Pallavicini, A., Pruzzo, C., & Vezzulli, L. (2019). Dynamics of the Pacific oyster pathobiota during mortality episodes in Europe assessed by 16S rRNA gene profiling and a new target enrichment next‐generation sequencing strategy. Environmental Microbiology. https://www.semanticscholar.org/paper/8134ad9468fbf645ba4b36d03a54363256d1f782

[2] Sáenz-Lahoya, S., Bitarte, N., García, B., Burgui, S., Vergara-Irigaray, M., Valle, J., Solano, C., Toledo-Arana, A., & Lasa, Í